stockrow
Friday 6 November 2026
Export PLYX’s income statement to Excel — free account
Polaryx Therapeutics, Inc.
PLYX Healthcare Biotechnology
1.80
0.00
0.00%
Follow PLYX
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
8.55 | 17.30 |
Net Debt/EBITDA |
0.66 | 1.06 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.44 | 0.08 |
| (193.70%) | 0.00% | |
| (176.68%) | 0.00% | |
ROIC |
0.00% | (2,989.01%) |
Return on Tangible Assets |
(196.82%) | (644.23%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(0.09) | (0.08) |
Cash per Share |
0.11 | 0.14 |
Shareholders Equity per Share |
0.10 | 0.14 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
0.10 | 0.14 |
Free Cash Flow |
(3.94) | (2.57) |
Working Capital |
4.57 | 4.71 |
Net Current Asset Value |
4.57 | 4.71 |
| Other line items | ||
Quick Ratio |
8.50 | 15.99 |
Cash ROIC |
(40.63%) | (27.57%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(0.09) | (0.08) |
Capex per Share |
0.00 | 0.00 |
Average Payables |
0.27 | — |
Average Assets |
5.09 | — |
Average Common Equity |
4.64 | — |
Columns are period end dates